Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 71.4%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%

Sorafenib vs pazopanib (targeted agent versus targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with pazopanib (targeted agent versus targeted agent) (very low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 0.92 [0.78, 1.09]
1 study · 366 participants
Very low

Sorafenib vs sunitinib (targeted agent versus targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with sunitinib (targeted agent versus targeted agent) (very low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 0.99 [0.85, 1.14]
1 study · 353 participants
Very low

Radioembolisation plus sorafenib vs sorafenib monotherapy

Serious adverse events · people with hepatocellular carcinoma

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 341 participants
Very low

Radioembolisation plus sorafenib vs sorafenib monotherapy

Non‐serious adverse events (hyperbilirubinaemia: most frequent) · people with hepatocellular carcinoma

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 341 participants
Very low

Radioembolisation vs sorafenib monotherapy

Serious adverse events · people with hepatocellular carcinoma

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 360 participants
Very low

Tivozanib vs sorafenib (targeted agent versus targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Tivozanib may leads to lower serious adverse events (Grade 3 or 4) compared with sorafenib (targeted agent versus targeted agent) (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 0.85 [0.74, 0.97]
1 study · 516 participants
Low

Radioembolisation vs sorafenib monotherapy

Non‐serious adverse events (hand‐foot skin reaction) · people with hepatocellular carcinoma

Radioembolisation may leads to lower non‐serious adverse events (hand‐foot skin reaction) compared with sorafenib (low certainty).

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
RR 0.02 [0, 0.06]
2 studies · 734 participants
Low